The penetration of fleroxacin into intra-abdominal abscesses

Youngs, Denise; Tudor, R. G.; Yoshioka, Kazuhiko; Keighley, M. R. B.

doi:10.1093/jac/22.supplement_d.115

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have indicated that fleroxacin ap pears to effectively treat a variety of infec tions, including both uncomplicated and com plicated urinary tract infections [16], bacterial sexually transmitted diseases such as Chlamy dia trachomatis [12,13], respiratory infections, intra-abdominal abscesses, and gastrointesti nal and skin and soft-tissue infections [14-16], In addition, fleroxacin achieves high levels in the sputum of cystic fibrosis patients [17] and in bone and synovial fluid [18].…”

Section: Introductionmentioning

confidence: 99%

The Comparative Activity of Fleroxacin, Three Other Quinolones and Eight Unrelated Antimicrobial Agents

McCarter

Mazens-Sullivan²,

Bartlett³

1992

Chemotherapy

View full text Add to dashboard Cite

The in vitro activity of fleroxacin, a new trifluorinated quinolone was evaluated against 432 bacterial isolates. Fleroxacin was 1- to 2-fold less active than ciprofloxacin and at least as active as ofloxacin and lomefloxacin against most members of the family Enterobacteriaceae. The MICs of fleroxacin for 90% of strains tested (MIC₉₀) were ≤0.25 μg/ml against all isolates of Enterobacteriaceae except Citrobacter freundii (MIC₉₀, 4 μg/ml) and Serratia marcescens (MIC₉₀, 2 μg/ml). Fleroxacin was as active as ciprofloxacin, ofloxacin and lomefloxacin against Pseudomonas spp, (MIC₉₀ for all quinolones tested were > 8 μg/ml). Acinetobacter and Haemophilus influenzae were very susceptible to fleroxacin; however fleroxacin was 1-fold less active than lomefloxacin against Acinetobacter and at least 1-fold less active than ciprofloxacin or ofloxacin against H. influenzae. Methicillin-susceptible and -resistant strains of Staphylococcus epidermidis and methicillin-susceptible strains of S. aureus were very susceptible to fleroxacin, with an MIC₉₀≤1 μg/ml (range 0.5-1 μg/ml). Methicillin-resistant S.aureus and Staphylococcus spp. other than aureus and epidermidis were not susceptible to fleroxacin (MIC₉₀ > 8 μg/ml). In addition, fleroxacin as well as ciprofloxacin, ofloxacin and lomefloxacin were inactive against Enterococcus spp. (MIC₉₀ > 8 μg/ml). Streptococcus pneumoniae and S. pyogenes were resistant to both fleroxacin and lomefloxacin but were very susceptible to ciprofloxacin and ofloxacin. These results suggest that fleroxacin represents a valid therapeutic option in the treatment of infections caused by most Enterobacteriaceae and some species of staphylococcus.

show abstract

Section: Introductionmentioning

confidence: 99%

The Comparative Activity of Fleroxacin, Three Other Quinolones and Eight Unrelated Antimicrobial Agents

McCarter

Mazens-Sullivan²,

Bartlett³

1992

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Several studies have been performed to evaluate the penetration of fluoroquinolones either in inflamed or non-inflamed intra-abdominal tissues both in human and in animals. In these studies, ciprofloxacin, [6][7][8][9][10][11][12][13] fleroxacin, 12,14 ofloxacin, 15 pefloxacin 16 and pazufloxacin 15 were evaluated. All of the studies reported high penetration of the administered compounds in the intra-abdominal tissues.…”

Section: Laboratory and Pharmacokinetic/ Pharmacodynamic Studiesmentioning

confidence: 99%

Systematic review: fluoroquinolones for the treatment of intra‐abdominal surgical infections

Falagas

Matthaiou

Bliziotis

2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Penetration of the drug into intra-abdominal abscesses was investigated in rats (Leibovitz et al 1989; Tudor et al 1988;Youngs et al 1988Youngs et al , 1989. Penetration of the drug into intra-abdominal abscesses was investigated in rats (Leibovitz et al 1989; Tudor et al 1988;Youngs et al 1988Youngs et al , 1989.…”

Section: Distributionmentioning

confidence: 99%

Fleroxacin Clinical Pharmacokinetics

Stuck

Kim

Frey

1992

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Fleroxacin is a new member of the class of fluoroquinolones. The drug has good activity (i.e. minimum inhibitory concentrations at less than 2 mg/L against 90% of strains) against a wide range of Gram-positive and Gram-negative bacteria. High performance liquid chromatography is used to determine concentrations of fleroxacin and its metabolites in biological fluids. Absorption of orally ingested drug is rapid as the peak plasma concentration of approximately 5 mg/L is reached in 1 to 2h after a single dose of 400mg. The systemic availability is close to 100%. Fleroxacin is poorly bound to plasma proteins (23%) and exhibits excellent tissue distribution. Renal clearance accounts for 60 to 70% of elimination. The drug is metabolised to form antimicrobially active N-demethyl-fleroxacin and inactive N-oxide-fleroxacin. In multiple dose studies the accumulation ratio of a once-daily dosage regimen is about 1.3, as predicted from the elimination half-life of 10 to 12h. Compared with ciprofloxacin, fleroxacin has a greater systemic availability and a longer half-life. Fleroxacin concentrations are higher in elderly patients, but further studies are needed to establish whether a dosage reduction should be recommended for this age group. In patients with renal disease dosage adjustment is recommended since a decreased renal clearance of fleroxacin leads to a significant prolongation of the elimination half-life. Fleroxacin is only poorly eliminated by peritoneal dialysis or haemodialysis. The most important drug-drug interaction is a decrease in systemic availability of fleroxacin after ingestion of aluminium- or magnesium-containing antacids. There is no evidence of a significant interaction between fleroxacin and theophylline. Only limited data are available on adverse reactions of fleroxacin. The most important adverse effects appear to be photosensitivity and a dose-dependent incidence of central nervous system reactions including sleep disorders.

show abstract

The penetration of fleroxacin into intra-abdominal abscesses

Cited by 8 publications

References 0 publications

The Comparative Activity of Fleroxacin, Three Other Quinolones and Eight Unrelated Antimicrobial Agents

The Comparative Activity of Fleroxacin, Three Other Quinolones and Eight Unrelated Antimicrobial Agents

Systematic review: fluoroquinolones for the treatment of intra‐abdominal surgical infections

Fleroxacin Clinical Pharmacokinetics

Contact Info

Product

Resources

About